Keymed Biosciences, Inc. (HK:2162) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Keymed Biosciences Inc. has shared positive results from a Phase I clinical study of their drug CMG901, a targeted treatment for advanced gastric cancer, at the ASCO Annual Meeting 2024. The study showed promising efficacy with a manageable safety profile for patients with Claudin 18.2-high G/GEJ cancer. Despite the encouraging data, the company cautions shareholders and potential investors that there’s no guarantee for the drug’s successful commercialization.
For further insights into HK:2162 stock, check out TipRanks’ Stock Analysis page.